Breaking News
Get 50% Off 0
😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingPro CLAIM SALE
Close

Immunomedics Inc (IMMU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Immunomedics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Immunomedics historical data, for real-time data please try another search
87.86 0.00    0.00%
22/10 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 87.59 - 87.93
Immunomedics 87.86 0.00 0.00%

Immunomedics Inc Company Profile

 
Get an in-depth profile of Immunomedics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products to treat cancer. The company develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. It focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for the treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. The company has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was incorporated in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Contact Information

Address 300 The American Road
Morris Plains, 07950
United States
Phone 973 605 8200
Fax 973 605 8282
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMMU Comments

Write your thoughts about Immunomedics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jim Saco
Jim Saco Oct 14, 2020 5:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I bought 300 shares under 85 and cashed out today at $87.56. Since I was in the margin made sense for me to forgo $132 and take the $800 profit.
ali ma
ali ma Oct 07, 2020 11:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
if I buy this share at current price@85 ... what will happen to my shares after the merge? my shares will be converted to gilead shares at what every price let say $65 + $88? so one share will be let say the current immu price $85- let say gilead$65 + 88? one share will be $153 instead of 173.does the symbol changes to gilead?
Jim Herbert
Jim77 Oct 07, 2020 11:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You will receive $88 cash for each share you hold. I don't think you'll receive Gilead shares.
ali ma
ali ma Sep 29, 2020 3:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🕷️ spider run run ... market crash is coming
Jim Saco
Jim Saco Sep 18, 2020 1:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I bought 200 shares at $84.64. Can't walk away from a 3.8% gain, even if I have to wait a month or two.
Jim Herbert
Jim77 Sep 18, 2020 1:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I believe it's a good move. Thinking about the same thing. Of course the only risk is the acquisition deal falling through (for whatever reason). In that unlikely case this would go back to $40-50 range.
Jim Saco
Jim Saco Sep 18, 2020 1:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Jim Herbert Doubt it. Both boards approved it unanimously.
Tejasvi Gogna
Tejasvi Gogna Sep 15, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Seems this will drop now
Jim Herbert
Jim77 Sep 15, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why really though? They are being acquired for $88 per share. Why would any shareholder sell significantly below that? There can be one reason: Betting on the acquisition decision by Gilead changing and it not happening eventually.
Farhad Ahmad
Farhad Ahmad Sep 15, 2020 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why is this stuck?
Jim Herbert
Jim77 Sep 15, 2020 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well, Gilead is gonna acquire them for $88 per share. So all shareholders will get $88 for each share they are holding. Currently why would anyone pay more than $88? Similarly, why would anyone sell it for less than $88? It should be stuck near $88 until the acquisition actually takes place in my opinion. Is this not the logic?
Emmanuel Domingo
Emmanuel Domingo Sep 14, 2020 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
50 by friday hold tight going doen to china-town!!
Ramone Bolton
Ramone Bolton Sep 14, 2020 1:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I put for put on it for like little 40 all 4 cast that I'm already up like 400 already but still I stand to lose 40 and to gain a couple 1000s so I'm good with that
Ramone Bolton
Ramone Bolton Sep 14, 2020 1:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
in my opinion anyone why buy this today good luck because you see how all this month been from it start one minute the market is up then next it's not so I wouldn't dare jump in on a buy worse it's the first of it jumping up
Farhad Ahmad
Farhad Ahmad Sep 14, 2020 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Law of gravity: What goes up must come down.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email